Rapamycin-eluting stent versus paclitaxel-eluting stent for coronary ostial lesions:effective and safety evaluation after 1-year follow-up
Chen Xiao-long
Abstract：BACKGROUND:Rapamycin and paclitaxel eluting stents have been widely used in the treatment of coronary ostial lesions (left main coronary artery and right coronary artery ostial lesions). However, the comparative researchon the effectiveness and safety of the two stentsfor coronary ostial lesions is relatively rare.
<br> OBJECTIVE:To explore the efficacy and safety of the rapamycin-eluting stentversuspaclitaxel-eluting stent in the treatment of coronary ostial lesions.
<br> METHODS:135 patients with coronary ostial lesions were selected and were alotted into two groups by random number table, 73 cases treated with rapamycin-eluting stentand the remaining 62 cases treated with paclitaxel-eluting stent.After 12-monthfolow-up, the incidence of adverse cardiac events, thrombosis, target lesion revascularization and stent-restenosis were compared between two groups.
<br> RESULTS AND CONCLUSION:Neither didstent dropoff or displace,nor didother adverse reactions related to the stent occurr in both two groups. The incidence of cardiac adverse events in the rapamycin group and paclitaxel group was 8.5% and 6.8%; the rate of thrombosis was 3.9% and 4.1%; the rate of the target lesion revascularization was 4.1% and 6.4%; the rate of stent-restenosis was 7.5% and 9.2%, respectively.Al above indicatorsshowedno significant differences between two groups. In conclusion, the efficacy and safety of the rapamycin-eluting stent for coronary ostial lesionsareequivalent to those of the paclitaxel-eluting stent.
Machine-generated Keywords：
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 5110-5115 )